Kane Biotech has entered into an exclusive agreement to distribute XSONX’s Wound Hygiene System in Australia, Canada, New Zealand and the Gulf Cooperation Council countries.
This five-year distribution agreement marks a significant expansion of Kane Biotech’s portfolio in the wound care market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The XSONX Wound Hygiene System is a cordless device equipped with vibrational debridement technology (VDT) that promotes microbleeding in the wound bed, which is essential for initiating the healing process.
It is designed to clean and debride chronic and contaminated wounds more effectively than manual methods.
The device’s scrubbing head is specifically engineered to maintain a positive wound healing trajectory. With the capability to deliver more than 500 micro-scrubs per second, the system’s powerful vibrations aim to reduce the pain associated with debridement while efficiently removing slough and biofilms.
Kane Biotech president and CEO Marc Edwards said: “The XSONX Wound Hygiene System is a proven contributor to chronic wound healing and will nicely complement Kane’s revyve product line.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“I am excited about this opportunity to partner with XSONX and to make their debridement tool widely available to wound care professionals via our distribution network.”
Kane Biotech is set to introduce XSONX to healthcare professionals in Canada at the upcoming Wounds Canada National Hybrid Conference.
The introduction will be in conjunction with its revyve antimicrobial wound gel and antimicrobial wound gel spray products.
In August this year, Kane Biotech secured a three-year agreement with Qatar Datamation Systems for the distribution of its revyve Antimicrobial Wound Gel in the wound care market. This agreement represents Kane Biotech’s fourth major distribution deal for revyve.
XSONX founder and CEO Dr Wade Farrow said: “According to recently released consensus documents, 60% of wounds in the US are under-debrided. I suspect this may be even higher in Canada and other international markets, making XSONX an important tool for practitioners.”
Kane Biotech’s portfolio of products includes DispersinB, coactiv, DermaKB and DermaKB Biofilm.
